



Association of 5-alpha-reductase inhibitor and prostate cancer incidence and mortality: a meta-analysis

Xu Hu^{1#}, Yao-Hui Wang^{1#}, Zhi-Qiang Yang^{1#}, Yan-Xiang Shao¹, Wei-Xiao Yang¹, Xiang Li²

¹West China School of Medicine/West China Hospital, Sichuan University, Chengdu, China; ²Department of Urology, West China Hospital, West China Medical School, Sichuan University, Chengdu, China

Contributions: (I) Conception and design: X Li, X Hu; (II) Administrative support: None; (III) Provision of study materials: X Li; (IV) Collection and assembly of data: X Hu, ZQ Yang, YH Wang, YX Shao; (V) Data analysis and interpretation: X Hu, YH Wang, WX Yang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work.

Correspondence to: Prof. Xiang Li. Department of Urology, West China Hospital, West China Medical School, Sichuan University, 37 Guoxue Street, Chengdu 610041, China. Email: hx_uro@sina.com.

Background: 5-Alpha-reductase inhibitors (5-ARIs) have been suggested as potential chemopreventive agents for prostate cancer (PCa). This study was conducted to evaluate the effect of 5-ARIs on the incidence and mortality of PCa.

Methods: The PubMed, Embase and Cochrane Library databases were searched comprehensively from database inception to October 2019. The clinical outcomes included the incidence of overall PCa, high-grade (Gleason 8–10) PCa, metastatic PCa, overall survival (OS), and cancer-specific survival (CSS).

Results: Overall, 23 studies were included in the present study, representing 11 cohort studies, 5 case-control studies, and 8 randomized controlled trials. The use of 5-ARIs was associated with a decreased risk of overall PCa [relative risk (RR) = 0.77; 95% CI: 0.67–0.88; P < 0.001] and increased risk of Gleason 8–10 PCa (RR = 1.19; 95% CI: 1.01–1.40; P = 0.036). In terms of metastatic PCa, there were no significant between-group differences (RR = 1.23; 95% CI: 0.69–2.18; P = 0.487). Furthermore, we found that prediagnostic 5-ARI usage was not associated with an increased risk of overall or prostate cancer mortality, with HRs of 1.00 (95% CI: 0.92–1.08; P = 0.938) and 0.98 (95% CI: 0.80–1.21; P = 0.881), respectively.

Conclusions: In conclusion, while male 5-ARI users were associated with a decreased risk of overall prostate cancer and increased risk of high-grade prostate cancer (Gleason 8–10), they were not associated with an increased risk of overall or prostate cancer mortality. 5-ARIs should be recommended carefully for use as chemopreventive agents.

Keywords: 5-alpha-reductase inhibitor; prostate cancer (PCa); incidence; mortality; meta-analysis

Submitted Apr 01, 2020. Accepted for publication Sep 11, 2020.

doi: 10.21037/tau-20-843

View this article at: <http://dx.doi.org/10.21037/tau-20-843>

Introduction

Prostate cancer (PCa) is the second most commonly diagnosed noncutaneous malignancy and the fifth leading cause of cancer mortality in men worldwide (1), and mortality from PCa (359,000 deaths in 2018) is markedly lower than PCa incidence (1.3 million new cases in 2018) (1). Due to the high occurrence of prostate cancer as well as the human and economic cost of treatment, preventive measures

would have a powerful impact on public health (2). In addition, PCa could be an ideal target for chemoprevention because of its attributes, such as long latency period and multistep pathogenesis (3).

5-alpha reductase inhibitors (5-ARIs), such as finasteride and dutasteride, are commonly used in the treatment of benign prostatic hyperplasia (BPH). They inhibit the conversion of testosterone to the more potent

dihydrotestosterone, which reduces the prostate volume and improves urinary flow obstruction (4). 5-ARIs have been suggested as potential chemopreventive agents for prostate cancer.

Two large randomized controlled trials (RCTs), the Prostate Cancer Prevention Trial (PCPT) and Reduction by Dutasteride of Prostate Cancer Events (REDUCE), showed 24.8% and 22.8% risk reductions in prostate cancer incidence with the use of 5-ARIs, respectively (5,6). However, both trials observed that 5-ARI users have an unexpected increased risk of high-grade tumors compared with placebo (5,6). Because it remains unknown whether the association was a result of bias, the utilization of 5-ARIs for chemoprevention is not endorsed.

It can be hypothesized that, because 5-ARIs increase the risk of high-grade tumors, they should increase the risk of prostate cancer outcomes, such as mortality. To date, several contradictory studies have explored the impact of 5-ARIs on prostate cancer outcomes (7-10). In addition, some studies did not detect an association between the use of 5-ARIs and increased risk of high-grade tumor (2,11). As a result, we performed the present study and summarized all relevant studies to evaluate the association between 5-alpha-reductase inhibitors and prostate cancer incidence and mortality. We present the current study in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting checklist (12) (available at <http://dx.doi.org/10.21037/tau-20-843>).

Methods

Literature search strategy

PubMed, Cochrane Library, and Embase were comprehensively searched from inception to October 2019. We adopted the following search items: 5-alpha reductase inhibitor (5-a-reductase inhibitor, 5-ARIs, finasteride, dutasteride, epristeride) and prostate cancer. We also reviewed reference lists of eligible studies to identify any additional relevant studies. Two investigators conducted the literature search independently, and any disagreement was resolved by consulting a third investigator.

Inclusion and exclusion criteria

We included studies that met the following criteria: (I) population-based studies; (II) 5-ARIs were used before the diagnosis of PCa; (III) compared 5-ARI users with

placebo or nonusers; (IV) reported clinical outcomes, such as prostate cancer incidence, mortality, or recurrence. We removed the following studies: (I) non-English language; (II) 5-ARIs were used after the diagnosis or treatment of PCa; (III) did not report relevant clinical outcomes; (IV) reviews and conference abstracts. For duplicated records, we only enrolled the study with the largest cases and most applicable information.

Data extraction and quality assessment

Two investigators independently extracted the following information from each study: first author's name, published year, study design, enrollment data and location, disease, drugs in experimental and control groups, number of cases, age, clinical outcomes, and the duration of follow-up. We evaluated the quality assessment observation studies and RCTs using the Newcastle-Ottawa Quality Assessment Scale (NOS) and the Cochrane Collaboration Risk of Bias Tool, respectively (13).

Statistical analysis

For prostate cancer incidence, we used relative risk (RR) as the statistic. For the clinical outcomes, such as overall survival (OS) and cancer-specific survival (CSS), the hazard ratio (HR) was applied. The heterogeneity among studies was evaluated by calculating the Q and I² statistics. If the I² statistics showed P<0.10 or I²>50%, a random-effect model was applied (14). Sensitivity analysis was carried out by repeating the meta-analysis after the removal of each study and assessing the robustness of the combined estimate. Concerning publication bias, we applied the Egger's test and Begg's test. If publication bias was detected, the trim and fill method was used to estimate the missing studies and recalculate the statistics (15). We also performed subgroup analysis and meta-regression to explore the potential source of heterogeneity. Statistical analyses were conducted using STATA version 12 (StataCorp, College Station, TX, USA). A two-sided P value <0.05 was regarded as statistically significant.

Results

Study selection

Our initial search strategy yielded 4,976 records, whose titles and abstracts were screened. After the removal of




Figure 1 Flow chart of the study selection.

duplicated records and initial screening, 81 studies were further reviewed in the full text. At the end of the process, 23 studies were confirmed to match the eligibility criteria and enrolled in the final analysis (2,5-10,16-31) (*Figure 1*).

Clinical characteristic of the enrolled studies

Overall, 23 studies were included in the present study. They included men from the United States, France, Sweden, Finland, and others. Of the included studies, 11 were cohort studies, 5 were case-control studies, and 8 were RCTs. One study consisted of a cohort and case-control study (8). Men in the 5-ARI group used finasteride or dutasteride, and men in the control group used α -blockers, non-5-ARIs or placebo. The sample sizes of the enrolled studies were relatively large except for one RCT, which enrolled less than 200 men. Most studies included men older than 65 years. Of the reported studies, the duration of follow-up was long, ranging from 1 year to 18 years. For the observation studies, we used the NOS to evaluate the quality assessment, and all studies were considered high

quality. The detailed information is summarized in *Table 1*. The quality assessment of RCT is presented in *Table S1*.

Overall prostate cancer

Concerning the incidence of overall PCa, 16 studies reported relevant information. We found that the use of 5-ARIs was associated with decreased risk of overall PCa, with an RR of 0.77 (95% CI: 0.67–0.88; $P < 0.001$; *Figure 2A*). We detected significant heterogeneity ($I^2 = 91.5\%$; $P < 0.001$); thus, we used the random-effect model. When stratified by study design, we also observed a significant association between the use of 5-ARIs and decreased risk of overall PCa in the cohort study (RR = 0.72; $P = 0.046$), case-control study (RR = 0.87; $P = 0.004$) and RCT (RR = 0.77; $P = 0.001$).

Gleason 8–10 prostate cancer

Fourteen studies revealed the incidence of Gleason 8–10 PCa. We observed that 5-ARI users had a significantly

Table 1 Clinical characteristics of included studies

Study/Published year	Enrollment date/location	Study type	Drug in 5ARIs group	Drugs in control group	Number of patients	Age (years), mean (SD)	Follow-up (years)	NOS
Van Rompay 2019 (16)	1995 and 2014/USA	Cohort study	Finasteride	a-blockers	5ARIs: 4,571 a-blockers: 7,764	70.0 (9.3)	Median 4.1	8
Scailteux 2019 (17)	2010 and 2013/France	Case-control	Dutasteride	Non-users	Non-user: 11,677 Cases: 767 Controls: 3,835	66.7 (9.7) 71.0 (8.5) 69.3 (8.6) 69.3 (8.6)	Median 6.3 Median 5.0 NA	8
Sarkar 2019 (9)	January 1 2001 and December 31 2015/USA	Cohort study	Finasteride	Non-users	5ARIs: 8,587 Non-users: 72,288	Median (IQR) 70 (64–76) Median (IQR) 65 (61–71)	Median (IQR) 5.9 (3.5–8.8)	8
Wallerstedt 2018 (18)	January 2007 and December 2015/Sweden	Cohort study	Finasteride	Non-users	5ARIs: 23,442 Non-users: 329,672	69 69	8 years	8
Murtola 2017 (19)	1995 and 2009/Finland	Cohort study	Finasteride	Non-users	5ARIs: 9,316 Non-users: 69,299	Median (IQR) 63 (59–67) Median (IQR) 59 (55–63)	NA	7
Milonas 2017 (20)	April 2007 and May 2011/Lithuania	RCT	Dutasteride	Surveillance	5ARIs: 68 Surveillance: 83	65.8 (6.6) 65.6 (6.7)	3 years	NA
Wallner 2016 (8)	1992 and 2007/USA	Matched cohort and nested case-control study	Finasteride	a-blockers	5ARIs: 25,388 a-blockers: 149,507 Prostate cancer death: 1,671	72.4 (9.3) 72.3 (9.2) 81.5 (8.1)	Median: 3.3 Median 2.3 Median 4.5	8
Murtola 2016 (7)	1995 and 2009/Finland	Cohort study	Finasteride	Non-users	No death: 16,640 5ARIs: 908 Non-users: 3,301	81.4 (8.0) Median (IQR) 70 (66–73) Median (IQR) 67 (63–70)	Median 5.3 Median 7.5 years	8
Azoulay 2015 (10)	1999 and 2009/UK	Cohort study	Finasteride	Non-users	5ARIs: 574 Non-users: 13,318	76.2 (8.2) 71.9 (9.2)	Mean 4.5	8
Preston 2014 (2)	1996 and 2010/USA	Cohort study	Finasteride	Non-users	5ARIs: 2,878 Non-users: 35,180	66.1 (8.6) 62.6 (9.2)	14 years	8
Thompson 2013 (21)	January 1994 and May 1997	RCT	Finasteride	Placebo	5ARIs: 9,423 Non-users: 9,457	NA	18 years	NA

Table 1 (continued)

Table 1 (continued)

Study/Published year	Enrollment date/location	Study type	Drug in 5ARIs group	Drugs in control group	Number of patients	Age (years), mean (SD)	Follow-up (years)	NOS
Robinson 2013 (22)	2007 and 2009/Sweden	Case-control	Finasteride	Non-users	Case: 26,735 control: 133,671	69.3 (9.1)	4 years	8
Kjellman 2013 (23)	1989 and 2006/Denmark	Cohort study	Dutasteride	Non-users	5ARIs: 199 Non-users: 2,806	73.9 (8.3)	Median 2.68, 2.62	7
Liang 2012 (24)	1996 and 2009/Taiwan	Case-control	Finasteride	Non-users	Case: 1,489 control: 4,331	72.5 (9.3)	NA	7
Hong 2012 (25)	2003 and 2010/Korea	Cohort study	Dutasteride	Non-users	5ARIs: 50	Median(range) 69 (54–82)	Median 23.5 months, 35 months	7
Ahmad 2012 (26)	1997 and 2010/UK	Cohort study	Dutasteride	Non-users	Non-users: 1,154 5ARIs: 143 Non-users: 1,990	66 (42–82)	Maximum 14 years	7
Roehrborn 2011 (27)	November 2003 and April 2009/multicenter	RCT	Dutasteride	Tamsulosin	5ARI: 1,623 a-blocker: 1,611	Median (IQR) 66 (61–71)	4 years	NA
Andriole 2010 (6)	March 2003 and April 2009/multicenter	RCT	Dutasteride	Placebo	5ARIs: 4,105 Non-users: 4,126	66 (61–71) 62.8 (6.04) 62.7 (6.08)	4 years	NA
Andriole 2004 (28)	Multicenter	RCT	Dutasteride	Placebo	5ARIs: 2,167 Non-users: 2,158	66.5 (7.6) 66.1 (7.4)	27 months	NA
Thompson 2003 (5)	January 1994 and May 1997/USA	RCT	Finasteride	Placebo	5ARIs: 9,423 Non-users: 9,457	≥55	7 years	NA
Irani 2002 (29)	January 1999 and June 2000/France	Case-control	Finasteride	Non-users	Case: 639 Control: 659	69 64.6	NA	7
Andriole 1998 (30)	December 1991 and December 1996/USA	RCT	Finasteride	Placebo	5ARI: 1,524 Non-users: 1,516	Range 45–78	4 years	NA
Cote 1998 (31)	USA	RCT	Finasteride	Non-users	5ARI: 27 Non-users: 25	≥50	1 year	NA

5ARIs, 5-alpha reductase inhibitors; SD, standard deviation; IQR, interquartile range; RCT, randomized controlled trial; NA, not available.

increased incidence of Gleason 8–10 PCa compared with nonusers, with an RR of 1.19 (95% CI: 1.01–1.40; $P=0.036$; *Figure 2B*). Because of the heterogeneity ($I^2=70.2\%$; $P<0.001$), the random-effect model was used. When stratified by study design, we found that 5-ARI users had a comparable risk of incidence of Gleason 8–10 PCa in the cohort study (RR =1.2; $P=0.06$), case-control study (RR =1.02; $P=0.703$) and RCT (RR =1.17; $P=0.575$).

Metastatic prostate cancer

Three cohort studies presented data describing the use of 5-ARIs and the incidence of metastatic PCa. There was significant heterogeneity among studies ($I^2=94.5\%$); thus, we used the random-effect model. We observed that the incidence of metastatic PCa was comparable between the two groups (RR =1.23; 95% CI: 0.69–2.18; $P=0.487$; *Figure 2C*).

Overall survival

In terms of overall survival, 6 studies reported relevant information for analysis. There was no significant difference in OS between 5-ARIs and nonusers, with an HR of 1.00 (95% CI: 0.92–1.08; $P=0.938$; $I^2=66.5\%$; *Figure 3A*). Similarly, no significant differences in OS was found between the two groups in the subgroup of the cohort study and RCT (HR =0.97, $P=0.632$; HR =1.03; $P=0.316$; respectively).

Cancer-specific survival

Regarding cancer-specific survival, 6 cohort studies evaluated the association between the 5-ARIs and CSS. As shown in *Figure 3B*, CSS was comparable between two groups, with an HR of 0.98 (95% CI: 0.80–1.21; $P=0.881$; $I^2=86.5\%$).

Sensitivity analysis and publication bias

We carried out the sensitivity analyses by removing each study in sequence to identify the robustness of our results. We did not observe large changes, which indicates the stability of the final results (*Figure 4*). We evaluated the publication bias for overall PCa and Gleason 8–10 PCa, and we did not observe significant publication bias based on the Egger's test ($P=0.169$, $P=0.079$; respectively) and Begg's test ($P=0.837$, $P=0.488$; respectively).

Meta-regression and subgroup analysis

According to the number of included studies, we carried out the meta-regression and meta-analyses for overall and Gleason 8–10 PCa based on the available results. Subgroup analyses were conducted based on the study design (cohort, case-control, RCT), the drugs in the control group (non-5-ARIs, α -blockers, and placebo), region (America, Europe, Asia, and multicenter), the duration of 5-ARI use (ever-use and long-term (>6 months) use) and the number of patients (<5,000 and $\geq 5,000$). In terms of overall PCa, we did not detect factors that had a significant impact on overall PCa. Nearly all subsets consistently showed that 5-ARIs were significantly associated with a decreased risk of overall PCa, except the Asia subgroup, which included only one study. Furthermore, the meta-regression indicated that the RRs of Gleason 8–10 PCa differed significantly according to the use group. The detailed information is presented in *Table 2*.

Discussion

The enzyme 5- α -reductase promotes the conversion of testosterone to the biologically potent form, dihydrotestosterone, which is important in prostate development and maintenance (32). 5-ARIs, including finasteride and dutasteride, inhibit the conversion of testosterone, leading to low intraprostatic levels of dihydrotestosterone and the subsequent induction of apoptosis (33,34). 5-ARIs are also commonly used in old men who suffer from BPH. Reportedly, two large scale RCT showed that 5-ARIs could decrease the risk of overall PCa, but they found that 5-ARI users had an increased risk of high-grade PCa (5,6). Whether 5-ARIs have an impact on the incidence of high-grade PCa and survival is controversial. Recently, several studies reported relevant outcomes. Therefore, we conducted the present study to evaluate the relationship between 5-ARIs and PCa incidence and mortality.

In the present study, we observed that 5-ARI usage was significantly associated with a decreased risk of overall PCa. In each subgroup, the results were similar. For high-grade PCa, the 5-ARI users had a significantly higher incidence of Gleason 8–10 PCa. When stratified by different variables, there were no significant differences in some subgroups. Furthermore, we found that duration of use might be the source of heterogeneity through the meta-regression. Some users are ever using, which means irregular use and may affect the results. As a result, the association between




Figure 2 The association between 5-ARI use and the incidence of (A) overall prostate cancer; (B) Gleason 8–10 prostate cancer; (C) metastatic prostate cancer. 5-ARI, 5-alpha-reductase inhibitors.




Figure 3 The association between 5-ARI use and (A) overall survival; (B) cancer-specific survival. 5-ARI, 5-alpha-reductase inhibitors.




Figure 4 Sensitivity analyses for (A) overall prostate cancer; (B) Gleason 8–10 prostate cancer.

Table 2 Meta-regression and subgroup analyses of overall and Gleason 8–10 PCa

Variable	Overall PCa			Gleason 8–10 PCa		
	Study	RR (95% CI)	P value	Study	RR (95% CI)	P value
Study design			0.784			0.567
Cohort study	5	0.72 (0.52–0.99)		6	1.20 (0.99–1.45)	
Case-control	4	0.85 (0.74–0.99)		2	1.15 (0.94–1.40)	
RCT	7	0.77 (0.67–0.90)		6	1.17 (0.68–1.99)	
Control group			0.772			0.507
Non-5ARIs	9	0.81 (0.69–0.96)		8	1.21 (1.03–1.43)	
a-blockers	2	0.64 (0.55–0.73)		2	0.97 (0.73–1.28)	
Placebo	6	0.79 (0.67–0.93)		5	1.35 (0.78–2.35)	
Region			0.868			0.797
America	5	0.70 (0.62–0.97)		5	1.27 (1.04–1.55)	
Europe	7	0.84 (0.71–0.98)		5	1.11 (0.91–1.34)	
Asia	1	1.24 (0.66–2.32)		1	1.52 (0.81–2.84)	
Multicenter	3	0.69 (0.51–0.93)		3	1.24 (0.76–2.03)	
Use			0.514			0.002
Ever-use	7	0.83 (0.60–1.00)		4	1.07 (0.95–1.20)	
Long-term use	11	0.76 (0.67–0.86)		12	1.35 (1.13–1.61)	
No. of patients			0.887			0.810
<5,000	8	0.80 (0.68–0.94)		7	1.14 (0.79–1.63)	
≥5,000	8	0.78 (0.67–0.92)		7	1.23 (1.04–1.45)	

PCa, prostate cancer; RR, relative ratio; CI, confidence interval; RCT, randomized controlled trial; 5-ARIs, 5-alpha reductase inhibitors; P value of random-effect meta-regression using restricted maximum likelihood (REML).

5-ARI usage and Gleason 8–10 PCa still needs to be explored. Regarding the metastatic PCa, we did not detect a significant difference between 5-ARI and non-5-ARI users. Furthermore, in terms of survival, we found that 5-ARIs did not have a significant effect on overall survival or cancer-specific survival.

Notably, our results showed a 23% reduction in overall PCa, which is similar to the previous report of two large scale RCT (5,6). Thompson *et al.* also collected data on the incidence of prostate cancer among PCPT participants for an additional year, and there was a significant between-group difference in the rates of overall PCa (RR =0.70; 95% CI: 0.65–0.76) (21). Recently, a retrospective 20-year cohort study, performed by Van Rompay *et al.*, revealed that the use of 5-ARIs was associated with a lower risk of PCa diagnosis compared with a-blocker users (HR =0.63; 95% CI: 0.54–

0.73) and nonusers (HR =0.61; 95% CI: 0.53–0.70) (8). In our subgroup analyses, we also observed similar results. We also detected a significant association between 5-ARI use and the incidence of overall PCa. A nest-control study revealed that finasteride use marginally increased the incidence of overall PCa but did not observe a similar result for dutasteride (24). A post hoc analysis of Asian men in the REDUCE study found that the incidence of prostate cancer in the dutasteride groups was lower than the placebo group (9.3% *vs.* 19.6%), but the difference was not significant (P=0.12) (35). For exposure time, Wallerstedt *et al.* found that treatment with 5-ARIs decreased the risk of overall PCa, and the effect was larger with longer time of exposure (0.1 to 2 years: HR =0.81, P=0.002; 2–4 years: HR =0.39, P<0.001; 4–6 years: HR =0.40, P<0.001; and 6–8 years: HR = 0.31, P=0.001) (18). Similarly, Robinson found that there

was a decrease in risk with increasing duration of 5-ARI exposure for overall PCa combined in men receiving 5-ARI treatment for more than three years ($P < 0.001$ for trend) (22).

Investigating the role of 5-ARIs in the development of high-grade PCa is an essential outcome to identify the potential harm and implications. Our results revealed that 5-ARI users had a significantly increased risk of Gleason 8–10 PCa. Meanwhile, in the different subgroups, the results were controversial, which may be due to the heterogeneity among studies. We conducted a meta-regression analysis and found that the duration of use may be the potential source of heterogeneity. Recently, a large cohort study observed that patients treated with 5-ARIs were more likely to have Gleason 8–10 PCa (25.2% *vs.* 17.0%; $P < 0.001$), which is in accordance with our findings (9). The increased proportion of high-grade prostate cancer among 5-ARI users has been suggested to be related more to bias than to biology (36,37). The increase in high-grade tumors seen in the previous studies may have resulted from detection bias through several mechanisms, including improved sensitivity of prostate-specific antigen testing and improved detection of small lesions of high-grade disease in the prostate after size reduction caused by 5-ARI treatments (11,36–39). However, we cannot exclude the possibility that the increase in high-grade tumors truly does result from detection bias. It is estimated that 150–270 men would need to be treated for 7 years with finasteride to cause one additional Gleason 8–10 PCa (7), which is line with our findings that exposure time might be the source of heterogeneity. However, few studies involved the relevant patients. Hence, the actual impact of 5-ARIs on high-grade disease still needs to be explored. Concerning metastatic PCa, we did not detect a significant between-group difference. However, likely due to the small numbers, the power of this result might be limited. The RR of metastatic PCa (1.23) is similar to the RR of Gleason 8–10 PCa (1.19); thus, the 5-ARIs might also be associated with an increased risk of metastatic PCa. Sarkar *et al.* observed that 5-ARI users are more likely to have metastatic disease (6.7% *vs.* 2.9%; $P < 0.001$), but they did not adjust for other variables (9). Meanwhile, Van Rompay *et al.* suggested that the incidence of metastatic PCa was not significantly different among 5-ARI users compared with nonusers or α -blocker users (adjusted HR: 1.12 and 0.89, respectively, $P = 0.54$ for both groups) (16). The studies included few metastatic disease patients, and further studies are required.

In the present study, although there was an elevated incidence of Gleason 8–10 PCa among 5-ARI users, this

did not translate into an increased risk of overall death or prostate cancer death. Thus, the increased incidence of high-grade tumors is more likely due to more accurate diagnostics. It was also suggested that the decreased risk of overall PCa did not translate into improved survival, supporting the previous reports that 5-ARIs mainly affect the incidence of low-risk disease that is unlikely to progress to the lethal stage. After 18 years of follow-up for PCPT participants, there was no significant between-group difference in overall survival (adjusted HR=1.03; $P = 0.26$) (21). Further, the Finnish Prostate Cancer Screening Trial observed that prediagnostic 5-ARI use was not associated with the risk of overall death or prostate cancer death (7). Stratification by amount, duration or intensity of 5-ARI use showed no survival trends. Van Rompay *et al.* also found that the use of 5-ARIs was not associated with a higher risk of PCa mortality regardless of comparison groups (16). However, Sarkar *et al.* suggested that 5-ARI users had worse overall survival (HR =1.10; $P < 0.001$) and cancer-specific survival (HR =1.39; $P < 0.001$) (9), although a lead-time bias may exist and affect the survival outcomes. These results are difficult to explain because PCa is not a common cause of death in the overall population, the generality of the results is limited by the highly selected populations, and the exposure rate is low (2,10,21). Few studies reported an association between 5-ARI usage and survival, and more well-conducted studies are essential.

Physicians who prescribe 5-ARIs for men with BPH struggle with the potentially increased risk of high-grade tumors (40). In our opinion, although 5-ARI users had potential increases in the risk of high-grade tumors, it did not translate into worse survival. These findings should provide reassurance to patients with BPH who are treated with these drugs. The controversies associated with this aspect lead to a general reluctance to recommend a 5-ARI chemoprevention strategies in men. Based on the evidence, 5-ARIs may not be fit for chemopreventive agents.

Our study has a number of strengths. We comprehensively searched the relevant articles and included 23 studies with a large number of cases. Therefore, this study was well powered. Furthermore, we investigated the relationship between 5-ARIs and the incidence of overall, high-grade (Gleason 8–10), metastatic PCa as well as its relationship with overall and prostate cancer-specific survival. The present study also included sensitivity analyses to identify the robustness of the final results. We also performed subgroup analyses and meta-regression based on all

available information to explore the potential source of heterogeneity.

Of course, our study is not devoid of limitations. First, although we included a large number of studies, most studies were observational studies with inherent bias, which may have affected the final results. Next, there were differences between studies, which may have resulted in heterogeneity. Much detailed information was not available; thus, we could not perform relevant analyses, such as subgroup analysis. Some studies performed the analysis adjusted for confounders, while others may not have been adjusted, and the models adjusted for the covariates were not the same. Last, studies that involved survival outcomes were scarce, which may have limited the power of the final results and prevented evaluation of safety.

Conclusions

In conclusion, while male 5-ARI users were associated with a decreased risk of overall prostate cancer and increased risk of high-grade prostate cancer (Gleason 8–10), they were not associated with an increased risk of overall or prostate cancer mortality. 5-ARIs should be recommended carefully for use as chemopreventive agents.

Acknowledgments

Funding: None.

Footnote

Reporting Checklist: The authors have completed the PRISMA reporting checklist. Available at <http://dx.doi.org/10.21037/tau-20-843>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.21037/tau-20-843>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68:394-424.
2. Preston MA, Wilson KM, Markt SC, et al. 5alpha-Reductase inhibitors and risk of high-grade or lethal prostate cancer. *JAMA Intern Med* 2014;174:1301-7.
3. Fitzpatrick JM, Schulman C, Zlotta AR, et al. Prostate cancer: a serious disease suitable for prevention. *BJU Int* 2009;103:864-70.
4. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. *N Engl J Med* 2003;349:2387-98.
5. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. *N Engl J Med* 2003;349:215-24.
6. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. *N Engl J Med* 2010;362:1192-202.
7. Murtola TJ, Karppe EK, Taari K, et al. 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial. *Int J Cancer* 2016;138:2820-8.
8. Wallner LP, DiBello JR, Li BH, et al. 5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia. *Mayo Clin Proc* 2016;91:1717-26.
9. Sarkar RR, Parsons JK, Bryant AK, et al. Association of Treatment With 5alpha-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer. *JAMA Intern Med* 2019;179:812-9.
10. Azoulay L, Eberg M, Benayoun S, et al. 5alpha-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer. *JAMA Oncol* 2015;1:314-20.
11. Redman MW, Tangen CM, Goodman PJ, et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. *Cancer Prev Res (Phila)* 2008;1:174-81.

12. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.
13. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *Bmj* 2011;343:d5928.
14. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *Bmj* 2003;327:557-60.
15. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics* 2000;56:455-63.
16. Van Rompay MI, Curtis Nickel J, Ranganathan G, et al. Impact of 5alpha-reductase inhibitor and alpha-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality. *BJU Int* 2019;123:511-8.
17. Scailteux LM, Rioux-Leclercq N, Vincendeau S, et al. Use of 5alpha-reductase inhibitors for benign prostate hypertrophy and risk of high grade prostate cancer: a French population-based study. *BJU Int* 2019;123:293-9.
18. Wallerstedt A, Strom P, Gronberg H, et al. Risk of prostate cancer in men treated with 5a-reductase inhibitors-a large population-based prospective study. *J Natl Cancer Inst* 2018;110:1216-21.
19. Murtola TJ, Virkku A, Talala K, et al. Outcomes of Prostate Cancer Screening by 5alpha-Reductase Inhibitor Use. *J Urol* 2017;198:305-9.
20. Milonas D ASSGGIJMJS. Dutasteride for the prevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia: results of a phase III randomized open-label 3-year trial. *World J Urol* 2017;35:721-8.
21. Thompson Jr IM, Goodman PJ, Tangen CM, et al. Long-term survival of participants in the prostate cancer prevention trial. *N Engl J Med* 2013;369:603-10.
22. Robinson D, Garmo H, Bill-Axelsson A, et al. Use of 5alpha-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. *BMJ* 2013;346:f3406.
23. Kjellman A, Friis S, Granath F, et al. Treatment with finasteride and prostate cancer survival. *Scand J Urol* 2013;47:265-71.
24. Liang JA, Sun LM, Lin MC, et al. A population-based nested case-control study in taiwan: use of 5alpha-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia. *Oncologist* 2012;17:986-91.
25. Hong SK, Oh JJ, Lee S, et al. Association of 5alpha-reductase inhibitor use and pathological features of prostate cancer in men undergoing radical prostatectomy. *Prostate* 2012;72:1187-92.
26. Ahmad I, Small DR, Krishna NS, et al. Prostate cancer incidence in patients on 5alpha-reductase inhibitors for lower urinary tract symptoms: A 14-year retrospective study. *Br J Med Surg Urol* 2012;5:179-83.
27. Roehrborn CG, Andriole GL, Wilson TH, et al. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial. *Eur Urol* 2011;59:244-9.
28. Andriole GL, Roehrborn C, Schulman C, et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. *Urology* 2004;64:537-41; discussion 542-3.
29. Irani J, Ravery V, Pariente JL, et al. Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. *J Urol* 2002;168:1985-8.
30. Andriole GL, Guess HA, Epstein JI, et al. Treatment with finasteride preserves usefulness of Prostate-Specific Antigen in the detection of prostate cancer: Results of a randomized, double-blind, placebo-controlled clinical trial. *Urology* 1998;52:195-201.
31. Cote RJ, Skinner EC, Salem CE, et al. The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. *Br J Cancer* 1998;78:413-8.
32. Thomas LN, Douglas RC, Lazier CB, et al. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. *Eur Urol* 2008;53:244-52.
33. Niu Y, Ge R, Hu L, et al. Reduced levels of 5-alpha reductase 2 in adult prostate tissue and implications for BPH therapy. *Prostate* 2011;71:1317-24.
34. McConnell JD, Wilson JD, George FW, et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. *J Clin Endocrinol Metab* 1992;74:505-8.
35. Akaza H, Kanetake H, Tsukamoto T, et al. Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian men: the results from the REDUCE study. *Jpn J Clin Oncol* 2011;41:417-23.
36. Andriole GL, Humphrey PA, Serfling RJ, et al. High-grade prostate cancer in the Prostate Cancer Prevention Trial: fact or artifact? *J Natl Cancer Inst* 2007;99:1355-6.
37. Goodman PJ, Thompson IM, Jr., Tangen CM, et al. The prostate cancer prevention trial: design, biases and interpretation of study results. *J Urol* 2006;175:2234-42.
38. Thompson IM, Chi C, Ankerst DP, et al. Effect of

- finasteride on the sensitivity of PSA for detecting prostate cancer. *J Natl Cancer Inst* 2006;98:1128-33.
39. Cohen YC, Liu KS, Heyden NL, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. *J Natl Cancer Inst* 2007;99:1366-74.
40. Thompson IM, Klein EA, Lippman SM, et al. Prevention of prostate cancer with finasteride: US/European perspective. *Eur Urol* 2003;44:650-5.

Cite this article as: Hu X, Wang YH, Yang ZQ, Shao YX, Yang WX, Li X. Association of 5-alpha-reductase inhibitor and prostate cancer incidence and mortality: a meta-analysis. *Transl Androl Urol* 2020;9(6):2519-2532. doi: 10.21037/tau-20-843